Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2020, Vol. 47 Issue (2): 147-153    DOI: 10.31083/j.ceog.2020.02.5140
Review | Next articles
Extracellular matrix metalloproteinases in the etiopathogenesis of endometriosis: a systematic review and critical appraisal
M. Ζafrakas1, 2, *(), Κ. Κοtronis1, P. Papasozomenou2, P. Eskitzis2, G. Grimbizis1
11st Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
2School of Health Science, International Hellenic University, Thessaloniki, Greece
Download:  PDF(1286KB)  ( 358 ) Full text   ( 19 )
Export:  BibTeX | EndNote (RIS)      

Despite extensive research in the field, the etiopathogenesis of endometriosis remains an unresolved enigma. The possible role of different enzymes of the extracellular matrix, in particular the role of the matrix metalloproteases or metalloproteinases (MMPs) in the etiopathogenesis and the mechanisms involved in the processes of benign dissemination of endometriosis have been widely investigated in recent years. Various members of the enzymatic system of the MMPs, as well as their inhibitors, termed tissue inhibitors of metalloproteinases (TIMPs) and their inducer, termed extracellular matrix metalloproteinase inducer (EMMPRIN), have been implicated in the mechanisms involved in endometriosis formation, progression, and maintenance. The aim of the present paper was to provide an overview and critical evaluation of existing experimental evidence on this issue. For this purpose the authors have conducted a systematic review of the literature and evaluated relevant papers regarding experimental animal models, in vitro experiments, and analyses in human samples and studies regarding genetic polymorphisms in humans. In conclusion, members of the system of matrix MMPs, their inhibitors and inducers could be useful as novel diagnostic and prognostic biomarkers in determining the severity of endometriosis and response to therapy. Furthermore, in depth knowledge in this field could possibly lead to the development of more efficient treatment modalities. Future research should focus on the systematic investigation of the entire MMPs system in endometriosis, as well as on the interaction between its members.

Key words:  Endometriosis      Etiopathogenesis      Extracellular matrix metalloproteases      Metalloproteinases      Tissue Inhibitors of metalloproteases      Extracellular matrix metalloproteinase inducer     
Published:  15 April 2020     
*Corresponding Author(s):  M. Ζafrakas     E-mail:

Cite this article: 

M. Ζafrakas, Κ. Κοtronis, P. Papasozomenou, P. Eskitzis, G. Grimbizis. Extracellular matrix metalloproteinases in the etiopathogenesis of endometriosis: a systematic review and critical appraisal. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 147-153.

URL:     OR

Table 1  — Overview of studies in experimental animal models regarding the matrix metalloproteinase (MMP) system.
Publication Animal model MMP-system member(s) Other factors Correlation of MMP
member with endometriosis
Paul et al. [8] Mouse proMMP-9, TIMP-1 Effect of Melatonin Yes / Yes
Paul et al. [9] Mouse MMP-3, MMP-9, TIMP-3 uPA; effect of Melatonin Yes / Yes / Yes
Machado et al. [10] Rat MMP-9 VEGF, Flk-1 Yes
Swarmakar and Paul [11] Mouse MMP-9 Effect of curcumin Yes
Chen et al. [12] Mouse MMP-2 and MMP-9 None Yes / Yes
Lu et al. [13] Mouse MMP-2 VEGF Yes
Wang and Ma [14] Nude mouse MMP-2, TIMP-2 Effects of E2 and progestin Yes / Yes
Bruner-Tran et al. [15] Nude mouse MMP-3, MMP-7 Effects of progesterone Yes / Yes
Bruner-Tran et al. [16] Mouse MMP-3, MMP-7 Effect of tanaproget Yes / Yes
Nothnick and Soloway [17] Mouse TIMP-1 Activated macrophages Yes
Stilley et al. [18] Rat TIMP-1 None Yes
Braundmeier et al. [19] Baboon EMMPRIN, MMPs None Yes / Yes
Table 2  — Overview of in vitro studies and studies in human samples regarding MMP-9.
Publication Type of sample MMP-system member(s) Other factors Correlation with
Chung et al. [20] ET MMP-9, TIMP-3 None Yes / Yes
Collete et al. [21] Cell culture MMP-9, MMP-2, TIMP-1 None Yes / No / Yes
Szymanowski et al. [22] ET, serum MMP-9, MMP-2, TIMP-1 TGF-β2 No / No / No
Collette et al. [23] ET MMP-9, TIMP-1 None Yes / Yes
Liu et al. [24] Serum, PF, ET MMP-9 None Yes
Liu et al. [25] Plasma, PF MMP-9 None Yes
Szamatowitcz et al. [26] PF MMP-9, TIMP-1 None Yes / Yes
Wu et al. [27] PF MMP-9, TIMP-1, TIMP-2 Effects of PGE2 Yes / Yes / Yes
De Sanctis et al. [28] Peripheral blood MMP-9, MMP-3 VEGF-A No / Yes
Salata et al. [29] Serum MMP-9, MMP-2, TIMP-1, TIMP-2 None No /No / No/ No
Yang et al. [30] Cell culture MMP-9 Osteopontin, E2 Yes
Zhang et al. [31] Cell culture MMP-9 Wnt signaling, E2 Yes
Table 3  — Overview of in vitro studies and studies in human samples regarding various members of the matrix metalloproteinase MMP-system other than MMP-9.
Publication Type of Sample MMP-system member(s) Other factors Correlation with
Hudelist et al. [32] ET MMP-1 Interleukin-1 Yes
Hudelist et al. [33] ET MMP-1 ER-alpha, ER-beta Yes
Juhasz-B?ss et al. [34] CAM MMP-1, MMP-2 None Yes / Yes
Huang et al. [35] PF and serum MMP-2 E2 and progesterone Yes
Kim et al. [36] ET MMP-2 VEGF, CD44, Ki-67 Yes
Jana et al. [37] ET MMP-2 VEGF, VEGFR-2, COX-2, vW Yes
Ramón et al. [38] ET MMP-3 uPA Yes
Gilabert-Estellés et al. [39] ET MMP-3, TIMP-1 uPA, PAI-1 Yes / Yes
Gilabert-Estellés et al. [40] PF MMP-3 VEGF, uPA Yes
Matsuzaki et al. [41] ET MMP-7 None Yes
Laudanski et al. [42] PF MMP-13, MMP-14, TIMP-2 None Yes / Yes / No
Gaetje et al. [43] ET MMP-24/25 None Yes
Sharpe-Timms et al. [44] PF, serum TIMP-1 Effect of GnRH-agonists Yes
Smedts et al. [45] ET EMMPRIN None Yes
Table 4  — Overview of studies regarding genetic polymorphisms of the MMP-system in humans.
Publication MMP-system member(s) Correlation with endometriosis
Ferrari et al. [46] MMP-1 and MMP-3 promoters No / No
Borghese et al. [47] MMP-12 and MMP-13 genes Yes, in combination, in superficial lesions
Han et al. [48] MMP-9 haplotypes and SNPs Yes for two haplotypes / No for 4 SNPs
Kang et al. [49] MMP-2, TIMP-2 No / Yes, protective role of TIMP-2
Cho et al. [50] MMP-2, TIMP-2 (10 SNPs) Yes, with advanced endometriosis
Ye et al. [51] MMP-1, MMP-2, MMP-3, MMP-9 Yes, for one MMP-1 polymorphism
Figure 1.  — Diagrammatic representation of the role of different members of the matrix metalloproteases (MMP) enzymatic system in endometriosis formation, maintenance, and progression.

[1] Dragoumis K., Mikos T., Zafrakas M., Assimakopoulos E., Stamatopoulos P., Bontis J.: “Endometriotic uterocutaneous fistula after cesarean section a case report”. Gynecol. Obstet. Invest., 2004, 57, 90.
doi: 10.1159/000075384 pmid: 14671417
[2] Pados G., Tympanidis J., Zafrakas M., Athanatos D., Bontis J.N. : “Ultrasound and MR-imaging in preoperative evaluation of two rare cases of scar endometriosis”. Cases J., 2008, 1, 97.
doi: 10.1186/1757-1626-1-97 pmid: 18706122
[3] Starzinski-Powitz A., Handrow-Metzmacher H., Kotzian S.: “The putative role of cell adhesion molecules in endometriosis: can we learn from tumour metastasis?” Mol. Med. Today, 1999, 5, 304.
doi: 10.1016/s1357-4310(99)01497-5 pmid: 10377522
[4] Zafrakas M., Tarlatzis B.C., Streichert T., Pournaropoulos F., Wölfle U., Smeets S.J. et al.: “Genome-wide microarray gene expression, array-CGH analysis and telomerase activity in advanced ovarian endometriosis: High degree of differentiation rather than malignant potential”. Int. J. Mol. Med., 2008, 21, 335.
pmid: 18288381
[5] Timologou A., Zafrakas M., Grimbizis G., Miliaras D., Kotronis K., Stamatopoulos P., Tarlatzis B.C.: “Immunohistochemical expression pattern of metastasis suppressors KAI1 and KISS1 in endometriosis and normal endometrium”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2016, 199, 110.
doi: 10.1016/j.ejogrb.2016.02.004 pmid: 26918694
[6] Zafrakas M., Grimbizis G., Timologou A., Tarlatzis B.C.: “Endometriosis and ovarian cancer risk: a systematic review of epidemiological studies”. Front. Surg., 2014, 1, 14.
doi: 10.3389/fsurg.2014.00014 pmid: 25593938
[7] Zhou H.E., Nothnick W.B.: “The relevancy of the matrix metalloproteinase system to the pathophysiology of endometriosis”. Front. Biosc., 2005, 10, 569.
doi: 10.2741/1552
[8] Paul S., Sharma A.V., Mahapatra P.D., Bhattacharya P., Reiter R.J., Swarnakar S.: “Role of melatonin in regulating matrix metalloproteinase-9 via tissue inhibitors of metalloproteinases during protection against endometriosis”. J. Pineal. Res., 2008, 44, 439.
doi: 10.1111/j.1600-079X.2007.00547.x pmid: 18298469
[9] Paul S., Bhattacharya P., Das Mahapatra P., Swarnakar S.: “Melatonin protects against endometriosis via regulation of matrix metalloproteinase-3 and an apoptotic pathway”. J. Pineal. Res., 2010, 49, 156.
doi: 10.1111/j.1600-079X.2010.00780.x pmid: 20609072
[10] Swarnakar S., Paul S.: “Curcumin arrests endometriosis by downregulation of matrix metalloproteinase-9 activity”. Indian Biochem. Biophys., 2009, 46, 59.
[11] Machado D.E., Berardo P.T., Palmero C.Y., Nasciutti L.E.: “Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases”. J. Exp. Clin. Cancer Res., 2010, 29, 4.
doi: 10.1186/1756-9966-29-4 pmid: 20085636
[12] Chen Q., Qiu N., Pu D., Zhou Y., Li T., Yang H.: “Change profiles in matrix metalloproteinase-2 and -9 in induced endometriosis in mice”. J. Huazhong Univ. Sci. Technolog. Med. Sci., 2010, 30, 188.
doi: 10.1007/s11596-010-0211-4 pmid: 20407871
[13] Lu X.E., Ning W.X., Dong M.Y., Liu A.X., Jin F., Huang H.F..: “Vascular endothelial growth factor and matrix metalloproteinase-2 expedite formation of endometriosis in the early stage ICR mouse model”. Fertil. Steril., 2006, 86, 1175.
doi: 10.1016/j.fertnstert.2005.12.083 pmid: 16962110
[14] Wang J., Ma X.: “Effects of estrogen and progestin on expression of MMP-2 and TIMP-2 in a nude mouse model of endometriosis”. Clin. Exp. Obstet. Gynecol., 2012, 39, 229.
pmid: 22905471
[15] Bruner-Tran K.L., Eisenberg E., Yeaman G.R., Anderson T.A., McBean J., Osteen K.G.: “Steroid and cytokine regulation of matrix metalloproteinase expression in endometriosis and the establishment of experimental endometriosis in nude mice”. J. Clin. Endocrinol. Metab., 2002, 87, 4782.
doi: 10.1210/jc.2002-020418 pmid: 12364474
[16] Bruner-Tran K.L., Zhang Z., Eisenberg E., Winneker R.C., Osteen K.G.: “Down-regulation of endometrial matrix metalloproteinase-3 and -7 expression in vitro and therapeutic regression of experimental endometriosis in vivo by a novel nonsteroidal progesterone receptor agonist, tanaproget”. J. Clin. Endocrinol. Metab., 2006, 91, 1554.
doi: 10.1210/jc.2005-2024 pmid: 16418212
[17] Nothnick W.B., Soloway P.D.: “Novel implications in the development of endometriosis: biphasic effect of macrophage activation on peritoneal tissue expression of tissue inhibitor of metalloproteinase-1”. Am. J. Reprod. Immunol., 1998, 40, 364.
doi: 10.1111/j.1600-0897.1998.tb00067.x pmid: 9870081
[18] Stilley J.A., Woods-Marshall R., Sutovsky M., Sutovsky P., Sharpe-Timms K.L.: “Reduced fecundity in female rats with surgically induced endometriosis and in their daughters: a potential role for tissue inhibitors of metalloproteinase 1”. Biol. Reprod., 2009, 80, 649.
doi: 10.1095/biolreprod.108.073411 pmid: 19020297
[19] Braundmeier A.G., Fazleabas A.T., Nowak R.A.: “Extracellular matrix metalloproteinase inducer expression in the baboon endometrium: menstrual cycle and endometriosis”. Reproduction, 2010, 140, 911.
doi: 10.1530/REP-09-0481 pmid: 20841363
[20] Chung H.W., Wen Y., Chun S.H., Nezhat C., Woo B.H., Lake Polan M.: “Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-3 mRNA expression in ectopic and eutopic endometrium in women with endometriosis: a rationale for endometriotic invasiveness”. Fertil. Steril., 2001, 75, 152.
doi: 10.1016/s0015-0282(00)01670-8 pmid: 11163831
[21] Collette T., Bellehumeur C., Kats R., Maheux R., Mailloux J., Villeneuve M., Akoum A.: “Evidence for an increased release of proteolytic activity by the eutopic endometrial tissue in women with endometriosis and for involvement of matrix metalloproteinase-9”. Hum. Reprod., 2004, 19, 1257.
doi: 10.1093/humrep/deh290 pmid: 15105396
[22] Szymanowski K., Mikołajczyk M., Wirstlein P., Dera-Szymanowska A.: “Matrix metalloproteinase-2 (MMP-2), MMP-9, tissue inhibitor of matrix metalloproteinases (TIMP-1) and transforming growth factor-β2 (TGF-β2) expression in eutopic endometrium of women with peritoneal endometriosis”. Ann. Agric. Environ. Med., 2016, 23, 649.
doi: 10.5604/12321966.1226861 pmid: 28030938
[23] Collette T., Maheux R., Mailloux J., Akoum A.: “Increased expression of matrix metalloproteinase-9 in the eutopic endometrial tissue of women with endometriosis”. Hum. Reprod., 2006, 21, 3059.
doi: 10.1093/humrep/del297 pmid: 16880228
[24] Liu H., Wang J., Wang H., Tang N., Li Y., Zhang Y., Hao T.: “The plasma and peritoneal fluid concentrations of matrix metallopro-teinase-9 are elevated in patients with endometriosis”. Ann. Clin. Biochem., 2016, 53, 599.
doi: 10.1177/0004563215626458 pmid: 26744503
[25] Liu H., Wang J., Wang H., Tang N., Li Y., Zhang Y., Hao T.: “Corre-lation between matrix etalloproteinase-9 and mendometriosis”. Int. J. Clin. Exp. Pathol., 2015, 8, 13399.
pmid: 26722547
[26] Szamatowicz J., Laudański P., Tomaszewska I.: “Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1: a possible role in the pathogenesis of endometriosis”. Hum. Reprod., 2002, 17, 284.
doi: 10.1093/humrep/17.2.284 pmid: 11821264
[27] Wu M.H., Shoji Y., Wu M.C., Chuang P.C., Lin C.C., Huang M.F., Tsai S.J. : “Suppression of matrix metalloproteinase-9 by prostaglandin E(2) in peritoneal macrophage is associated with severity of endometriosis”. Am. J. Pathol., 2005, 167, 1061.
doi: 10.1016/S0002-9440(10)61195-9 pmid: 16192641
[28] De Sanctis P., Elmakky A., Farina A., Caramelli E., Seracchioli R., Mabrouk M. et al.: “Matrix metalloproteinase-3 mRNA: a promising peripheral blood marker for diagnosis of endometriosis”. Gynecol. Obstet. Invest., 2011, 71, 118.
doi: 10.1159/000320752 pmid: 21150162
[29] Salata I.M., Stojanovic N., Cajdler-Łuba A., Lewandowski K.C., Lewiński A.: “Gelatinase A (MMP-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis”. Gynecol. Endocrinol., 2008, 24, 326.
doi: 10.1080/09513590802090325 pmid: 18584412
[30] Yang M., Jiang C., Chen H., Nian Y., Bai Z., Ha C.: “The involvement of osteopontin and matrix metalloproteinase-9 in the migration of endometrial epithelial cells in patients with endometriosis”. Reprod. Biol. Endocrinol., 2015, 13, 95.
doi: 10.1186/s12958-015-0090-4 pmid: 26289107
[31] Zhang L., Xiong W., Xiong Y., Liu H., Li N., Du Y., Liu Y.: “Intracellular Wnt/Beta-Catenin Signaling Underlying 17beta-Estradiol-Induced Matrix Metalloproteinase 9 Expression in Human Endometriosis”. Biol. Reprod., 2016, 94, 70.
doi: 10.1095/biolreprod.115.135574 pmid: 26888969
[32] Hudelist G., Lass H., Keckstein J., Walter I., Wieser F., Wenzl R., et al.: “Interleukin 1alpha and tissue-lytic matrix metalloproteinase-1 are elevated in ectopic endometrium of patients with endometriosis”. Hum. Reprod., 2005, 20, 1695.
doi: 10.1093/humrep/deh794 pmid: 15746198
[33] Hudelist G., Keckstein J., Czerwenka K., Lass H., Walter I., Auer M., et al.: “Estrogen receptor beta and matrix metalloproteinase 1 are coexpressed in uterine endometrium and endometriotic lesions of patients with endometriosis”. Fertil. Steril., 2005, 84, 1249.
doi: 10.1016/j.fertnstert.2005.06.014 pmid: 16210018
[34] Juhasz-Böss I., Hofele A., Lattrich C., Buchholz S., Ortmann O., Malik E.: “Matrix metalloproteinase messenger RNA expression in human endometriosis grafts cultured on a chicken chorioallantoic membrane”. Fertil. Steril., 2010, 94, 40.
doi: 10.1016/j.fertnstert.2009.02.052
[35] Huang H.F., Hong L.H., Tan Y., Sheng J.Z.: “Matrix metalloproteinase 2 is associated with changes in steroid hormones in the sera and peritoneal fluid of patients with endometriosis”. Fertil. Steril., 2004, 81, 1235.
doi: 10.1016/j.fertnstert.2003.10.027
[36] Kim H.O., Yang K.M., Kang I.S., Koong M.K., Kim H.S., Zhang X., Kim I.: “Expression of CD44s, vascular endothelial growth factor, matrix metalloproteinase-2 and Ki-67 in peritoneal, rectovaginal and ovarian endometriosis”. J. Reprod. Med., 2007, 52, 207.
pmid: 17465288
[37] Jana S., Chatterjee K., Ray A.K., DasMahapatra P., Swarnakar S.: “Regulation of Matrix Metalloproteinase-2 Activity by COX-2-PGE2-pAKT Axis Promotes Angiogenesis in Endometriosis”. PLoS One, 2016, 11, e0163540.
doi: 10.1371/journal.pone.0163540 pmid: 27695098
[38] Ramón L., Gilabert-Estellés J., Castelló R., Gilabert J., España F., Romeu A., et al.: “mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay”. Hum. Reprod., 2005, 20, 272.
doi: 10.1093/humrep/deh571 pmid: 15579491
[39] Gilabert-Estellés J., Estellés A., Gilabert J., Castelló R., España F., Falcó C., et al.: “Expression of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis”. Hum. Reprod., 2003, 18, 1516.
doi: 10.1093/humrep/deg300 pmid: 12832381
[40] Gilabert-Estellés J., Ramón L.A., España F., Gilabert J., Vila V., Réganon E., Castelló R., et al.: “Expression of angiogenic factors in endometriosis: relationship to fibrinolytic and metalloproteinase systems”. Hum. Reprod., 2007, 2, 2120.
[41] Matsuzaki S., Maleysson E., Darcha C.: “Analysis of matrix metalloproteinase-7 expression in eutopic and ectopic endometrium samples from patients with different forms of endometriosis”. Hum. Reprod., 2010, 25, 742.
doi: 10.1093/humrep/dep435 pmid: 20007614
[42] Laudanski P., Szamatowicz J., Ramel P.: “Matrix metalloproteinase-13 and membrane type-1 matrix metalloproteinase in peritoneal fluid of women with endometriosis”. Gynecol. Endocrinol., 2005, 21, 106.
doi: 10.1080/09513590500154043 pmid: 16109597
[43] Gaetje R., Holtrich U., Engels K., Kourtis K., Cikrit E., Kissler S., et al.: “Expression of membrane-type 5 matrix metalloproteinase in human endometrium and endometriosis”. Gynecol. Endocrinol., 2007, 23, 567.
doi: 10.1080/09513590701556921 pmid: 17952761
[44] Sharpe-Timms K.L., Keisler L.W., McIntush E.W., Keisler D.H.: “Tissue inhibitor of metalloproteinase-1 concentrations are attenuated in peritoneal fluid and sera of women with endometriosis and restored in sera by gonadotropin-releasing hormone agonist therapy”. Fertil. Steril., 1998, 69, 1128.
doi: 10.1016/s0015-0282(98)00075-2 pmid: 9627304
[45] Smedts A.M., Lele S.M., Modesitt S.C., Curry T.E.: “Expression of an extracellular matrix metalloproteinase inducer (basigin) in the human ovary and ovarian endometriosis”. Fertil. Steril., 2006, 86, 535.
doi: 10.1016/j.fertnstert.2006.01.042
[46] Ferrari M.M., Biondi M.L., Rossi G., Grijuela B., Gaita S., Perugino G., Viganò P.: “Analysis of two polymorphisms in the promoter region of matrix metalloproteinase 1 and 3 genes in women with endometriosis”. Acta Obstet. Gynecol. Scand., 2006, 85, 212.
doi: 10.1080/00016340500345287 pmid: 16532917
[47] Borghese B., Chiche J.D., Vernerey D., Chenot C., Mir O., Bijaoui G., et al.: “Genetic polymorphisms of matrix metalloproteinase 12 and 13 genes are implicated in endometriosis progression”. Hum. Reprod., 2008, 23, 1207.
doi: 10.1093/humrep/den007 pmid: 18308831
[48] Han Y.J., Kim H.N., Yoon J.K., Yi S.Y., Moon H.S., Ahn J.J., et al.: “Haplotype analysis of the matrix metalloproteinase-9 gene associated with advanced-stage endometriosis”. Fertil. Steril., 2009, 91, 2324.
doi: 10.1016/j.fertnstert.2008.03.047
[49] Kang S., Zhao X.W., Wang N., Chen S.C., Zhou R.M., Li Y.: “Association of polymorphisms of the MMP-2 and TIMP-2 genes with the risk of endometriosis in North Chinese women”. Fertil. Steril., 2008, 90, 2023.
doi: 10.1016/j.fertnstert.2007.09.068 pmid: 18177649
[50] Cho Y.J., Kim N.H., Jeong K.A., Lee J.Y., Moon H.S., Kim H.L., Chung H.W.: “Association between MMP-2 and TIMP-2 gene polymorphisms and advanced-stage endometriosis in Korean women”. Am. J. Reprod. Immunol., 2013, 69, 73.
doi: 10.1111/aji.12020
[51] Ye H., He Y., Wang J., Song T., Lan Z., Zhao Y., Xi M.: “Effect of matrix metalloproteinase promoter polymorphisms on endometriosis and adenomyosis risk: evidence from a meta-analysis”. J. Genet., 2016, 95, 611.
doi: 10.1007/s12041-016-0675-5 pmid: 27659332
[52] Tang L., Xiang Y., Zhou Y., Mu J., Zai M., Xing Q., et al.: “The DNA methylation status of genes encoding Matrix metalloproteinases and tissue inhibitors of Matrix metalloproteinases in endometriosis”. Mol. Reprod. Dev., 2018, 85, 17.
doi: 10.1002/mrd.22931 pmid: 29266528
[1] Y.A. Kim. Mature cystic teratoma of the uterus presenting as an endometrial polyp in a patient with a history of ovarian mature cystic teratoma with gliomatosis peritonei and ovarian endometriosis: a case report[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 800-804.
[2] H. Takagi, S. Yamada, J. Sakamoto, S. Fujita, T. Sasagawa. Hemostatic effects of kyukikyogaito in dienogest treatment[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 560-564.
[3] K. Chmaj-Wierzchowska, M. Wojciechowska, I. Parda, K. Plagens-Rotman, P. Rzymski, M. Wilczak. How do health problems affect the quality and everyday life of patients with endometriomas?[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 571-575.
[4] X.J. Shi, L.B. Shi, S.Y. Zhang. Mechanistic study of vitamin C attenuation of endometriotic fibrosis[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(3): 383-390.
[5] K.Y. Yun, S.Y. Hwang, H.J. Lee, S.C. Kim, J.K. Joo, D.S. Suh, K.H. Kim, K.S. Lee. The association of body mass index with incidence, stage and recurrence of endometriosis: case-control study in Korean women[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(1): 53-56.
[6] Hue HJ, Kim SK, Choi JY, Suh DH, Kim KD, No JH, Lee JR, Jee BC, Kim YB, Jeon HW. Previous ovarian surgery increases the risk of tubal factor infertility[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(1): 84-88.
[7] H.-H. Lee, M.-J. Mun, T.-H. Kim, Y.-S. Kim, W.-C. Jang, J.-Y. Hwang. Relationships between vitamin D receptor genetic polymorphisms and endometriosis in Korean women[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 876-880.
[8] A. Vitagliano, A. Andrisani, F. Dessole, G. Virdis, R. Cappadona, L. Marin, G. Capobianco, S. Dessole, G. Ambrosini. Rectovaginal endometriosis: head to head comparison between sonovaginography and magnetic resonance imaging[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 888-891.
[9] C. Hayashi, K. Matsumoto, K. Shinya, T. Nakajima, T. Nakao, A. Komatsu, F. Chishima, K. Kawana. The expression of angiotensin II receptors mRNA in granulosa-lutein cells in endometriosis patients who underwent ovarian surgery before in vitro fertilization[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 910-913.
[10] Songping Liu, Xin Tian, Hongyan Cui, Qiong Zhang, Keqin Hua. Feasibility of serum-free culture in isolating endometriotic stem cells[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 920-923.
[11] M. Paliga, S. Horák. Relationship between endometriosis and vitamin D status – a review[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 674-678.
[12] R. T. Ratner, A. Harris, J. Tsaltas, N. Goyal, M. Davies-Tuck, H. Najjar, O. Barel. An eight-year retrospective analysis of laparoscopic surgery for endometriosis, outcomes and complications in a large multicenter unit[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 699-703.
[13] Y.-S. Kim, J.-Y. Hwang, T.-H. Kim, E.-G. Lee, H.-H. Lee. Genome-wide association study of recurrent endometriosis related with ovarian cancer[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(4): 553-559.
[14] K. Nakamura, K. Nakayama, T. Minamoto, T. Ishibashi, K. Sanuki, H. Yamashita, R. Ono, H. Sasamori, S. Razia, M.M. Hossain, S. Kamrunnahar, M. Ishikawa, S. Kyo. A novel retrograde approach for total laparoscopic hysterectomy in patients with severe adhesion in the cul-de-sac[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(4): 565-569.
[15] H. Takagi, J. Sakamoto, T. Sasagawa. Long-term treatment of endometriosis with dienogest for up to five years[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(3): 398-402.
No Suggested Reading articles found!